ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having an overwhelmingly strong start to the trading session this morning after announcing poster presentation sof clinical data surrounding Parkinson’s disease that have been presented at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles.
ACAD Heads For The Top On Data Presentations
As mentioned above, ACADIA Pharmaceuticals is having an incredibly strong start to the trading session this morning. The gains are ultimately the result of presentations provided by the company surrounding clinical experience data from two studies of NUPLAZID® for the treatment of Parkinson’s disease psychosis (PD Psychosis). The presentations were given at the American Academy of Neurology Annual Meeting in Los Angeles.
The first of the presentations provided by ACAD was titled “Clinical Experience with Pimavanserin for Treatment of Parkinson’s Disease Psychosis”. The presentation outlined that 70% of patients treated with NUPLAZID reported clinical improvement with 88% of patients treated longer than 4 weeks seeing improvement. Also 67% of patients remained on the treatment for an average of 10+ months while only 11% of patients were unable to tolerate the treatment due to adverse events. Also, with only 6 of 88 patients passing away during the study, there is was no increase in mortality rate observed. In a statement, Daniel Classen, MD, Associate Professor of Neurology at Vanderbilt University Medical Center, had the following to offer with regard to the data.
This retrospective chart review provides relevant clinical experience data on treatment patterns in a Parkinson’s disease psychosis cohort… At about ten months of follow-up, we see that two-thirds of patients have noted a favorable clinical response to NUPLAZID. We look forward to continuing our studies of how to treat psychosis in Parkinson’s disease, as we assess treatment strategies for this debilitating symptom.
The second poster provided by ACAD was titled “Pimavanserin Use in a Movement Disorders Clinic: a Single Center Experience”. During this study, 65% of patients reported improvement with regard to hallucinations when treated with NUPLAZID. Also 6 of 9 patients that were originally prescribed earlier generation antipsychotic medications were able to discontinue these previously prescribed medications. Finally, no major side effects were reported. In a statement, Neepa Patel, MD, Movement Disorder Specialist at Henry Ford Hospital in West Bloomfield, MI, had the following to say about the data presented by ACAD:
Our study was based on real-life experience and shows that NUPLAZID is a beneficial and well-tolerated treatment for PD Psychosis.
What We’re Seeing From The Stock
As we know, one of the primary drivers of movement in the market is news. In the case of ACADIA Pharmaceuticals, the news proved to be overwhelmingly positive. So, it’s no surprise that we’re seeing a strong positive reaction in the market today. At the moment (10:41), ACAD is trading at $16.32 per share after a gain of $1.20 per share or 7.90% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ACAD. In particular, we’re interested in following the ongoing development of NUPLAZID as the treatment seems to be producing some seriously positive results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!